In cancer, the non-genomic inhibition of PP2A activity by elevated expression of endogenous PP2A inhibitor proteins (PAIPs), such as CIP2A, SET, PME1, ARPP19 and TIPRL, greatly exceeds the frequency of genetic mutations on PP2A genes [9]. The gene discussed is CIP2A; the disease is cancer.